#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=3. Tailoring Immunotherapy in Real-Life Clinical Practice
1-1	0-2	3.	_	_	_	_
1-2	3-12	Tailoring	_	_	_	_
1-3	13-26	Immunotherapy	abstract	new	coref	2-20[13_0]
1-4	27-29	in	_	_	_	_
1-5	30-39	Real-Life	abstract[3]	new[3]	coref	5-15[44_3]
1-6	40-48	Clinical	substance|abstract[3]	new|new[3]	_	_
1-7	49-57	Practice	abstract[3]	new[3]	_	_

#Text=After the histology-agnostic approval of pembrolizumab in mismatch repair ( MMR)-deficient tumors , the predictive molecular pathology scenario in cancer immunotherapy changed radically .
2-1	58-63	After	_	_	_	_
2-2	64-67	the	abstract[4]	new[4]	_	_
2-3	68-86	histology-agnostic	abstract[4]	new[4]	_	_
2-4	87-95	approval	abstract[4]	new[4]	_	_
2-5	96-98	of	abstract[4]	new[4]	_	_
2-6	99-112	pembrolizumab	abstract[4]|substance	new[4]|new	_	_
2-7	113-115	in	abstract[4]	new[4]	_	_
2-8	116-124	mismatch	abstract[4]|object|abstract[7]	new[4]|new|new[7]	_	_
2-9	125-131	repair	abstract[4]|abstract[7]	new[4]|new[7]	_	_
2-10	132-133	(	_	_	_	_
2-11	134-148	MMR)-deficient	object[8]	new[8]	_	_
2-12	149-155	tumors	object[8]|object	new[8]|new	coref	10-6[63_0]
2-13	156-157	,	_	_	_	_
2-14	158-161	the	abstract[11]	new[11]	_	_
2-15	162-172	predictive	abstract[11]	new[11]	_	_
2-16	173-182	molecular	abstract[11]	new[11]	_	_
2-17	183-192	pathology	abstract|abstract[11]	new|new[11]	_	_
2-18	193-201	scenario	abstract[11]	new[11]	_	_
2-19	202-204	in	abstract[11]	new[11]	_	_
2-20	205-211	cancer	abstract[11]|abstract|abstract[13]	new[11]|new|giv[13]	coref|coref	4-11[27_13]|4-11[27_13]
2-21	212-225	immunotherapy	abstract[11]|abstract[13]	new[11]|giv[13]	_	_
2-22	226-233	changed	_	_	_	_
2-23	234-243	radically	_	_	_	_
2-24	244-245	.	_	_	_	_

#Text=For the first time in the history of medicine , a drug ( in this case , an immune-checkpoint inhibitor ) was approved based on a specific molecular feature of the neoplasm , irrespective of its anatomical site of origin .
3-1	246-249	For	_	_	_	_
3-2	250-253	the	time[14]	new[14]	coref	14-33[98_14]
3-3	254-259	first	time[14]	new[14]	_	_
3-4	260-264	time	time[14]	new[14]	_	_
3-5	265-267	in	time[14]	new[14]	_	_
3-6	268-271	the	time[14]|time[15]	new[14]|new[15]	_	_
3-7	272-279	history	time[14]|time[15]	new[14]|new[15]	_	_
3-8	280-282	of	time[14]|time[15]	new[14]|new[15]	_	_
3-9	283-291	medicine	time[14]|time[15]|abstract	new[14]|new[15]|new	_	_
3-10	292-293	,	_	_	_	_
3-11	294-295	a	substance[17]	new[17]	coref	19-20[133_17]
3-12	296-300	drug	substance[17]	new[17]	_	_
3-13	301-302	(	_	_	_	_
3-14	303-305	in	_	_	_	_
3-15	306-310	this	abstract[18]	new[18]	_	_
3-16	311-315	case	abstract[18]	new[18]	_	_
3-17	316-317	,	_	_	_	_
3-18	318-320	an	object[19]	new[19]	ana	3-36[0_19]
3-19	321-338	immune-checkpoint	object[19]	new[19]	_	_
3-20	339-348	inhibitor	object[19]	new[19]	_	_
3-21	349-350	)	_	_	_	_
3-22	351-354	was	_	_	_	_
3-23	355-363	approved	_	_	_	_
3-24	364-369	based	_	_	_	_
3-25	370-372	on	_	_	_	_
3-26	373-374	a	abstract[20]	new[20]	_	_
3-27	375-383	specific	abstract[20]	new[20]	_	_
3-28	384-393	molecular	abstract[20]	new[20]	_	_
3-29	394-401	feature	abstract[20]	new[20]	_	_
3-30	402-404	of	abstract[20]	new[20]	_	_
3-31	405-408	the	abstract[20]|object[21]	new[20]|new[21]	_	_
3-32	409-417	neoplasm	abstract[20]|object[21]	new[20]|new[21]	_	_
3-33	418-419	,	_	_	_	_
3-34	420-432	irrespective	_	_	_	_
3-35	433-435	of	_	_	_	_
3-36	436-439	its	object|place[23]	giv|new[23]	_	_
3-37	440-450	anatomical	place[23]	new[23]	_	_
3-38	451-455	site	place[23]	new[23]	_	_
3-39	456-458	of	place[23]	new[23]	_	_
3-40	459-465	origin	place[23]|abstract	new[23]|new	_	_
3-41	466-467	.	_	_	_	_

#Text=A multitude of different tools has been proposed to inform immunotherapy , including morphology , immunohistochemistry ( IHC ) , polymerase chain reaction ( PCR)-based techniques and next-generation technology assays , such as next-generation sequencing ( NGS ) or multiplex barcode technology ( e. g. , NanoString ) .
4-1	468-469	A	abstract[25]	new[25]	_	_
4-2	470-479	multitude	abstract[25]	new[25]	_	_
4-3	480-482	of	abstract[25]	new[25]	_	_
4-4	483-492	different	abstract[25]|object[26]	new[25]|new[26]	coref	5-4[41_26]
4-5	493-498	tools	abstract[25]|object[26]	new[25]|new[26]	_	_
4-6	499-502	has	_	_	_	_
4-7	503-507	been	_	_	_	_
4-8	508-516	proposed	_	_	_	_
4-9	517-519	to	_	_	_	_
4-10	520-526	inform	_	_	_	_
4-11	527-540	immunotherapy	abstract[27]	giv[27]	coref	8-8[0_27]
4-12	541-542	,	abstract[27]	giv[27]	_	_
4-13	543-552	including	abstract[27]	giv[27]	_	_
4-14	553-563	morphology	abstract[27]|abstract	giv[27]|new	_	_
4-15	564-565	,	abstract[27]	giv[27]	_	_
4-16	566-586	immunohistochemistry	abstract[27]|abstract	giv[27]|new	appos	4-18
4-17	587-588	(	abstract[27]	giv[27]	_	_
4-18	589-592	IHC	abstract[27]|abstract	giv[27]|giv	coref	17-4[115_0]
4-19	593-594	)	abstract[27]	giv[27]	_	_
4-20	595-596	,	abstract[27]	giv[27]	_	_
4-21	597-607	polymerase	abstract[27]|abstract[31]	giv[27]|new[31]	appos	4-25[32_31]
4-22	608-613	chain	abstract[27]|abstract[31]	giv[27]|new[31]	_	_
4-23	614-622	reaction	abstract[27]|abstract[31]	giv[27]|new[31]	_	_
4-24	623-624	(	abstract[27]	giv[27]	_	_
4-25	625-635	PCR)-based	abstract[27]|abstract[32]	giv[27]|giv[32]	coref	19-3[128_32]
4-26	636-646	techniques	abstract[27]|abstract[32]	giv[27]|giv[32]	_	_
4-27	647-650	and	abstract[27]|abstract[32]	giv[27]|giv[32]	_	_
4-28	651-666	next-generation	abstract[27]|abstract[32]	giv[27]|giv[32]	_	_
4-29	667-677	technology	abstract[27]|abstract[32]|abstract	giv[27]|giv[32]|new	coref	4-40[39_0]
4-30	678-684	assays	abstract[27]|abstract[32]	giv[27]|giv[32]	_	_
4-31	685-686	,	abstract[27]|abstract[32]	giv[27]|giv[32]	_	_
4-32	687-691	such	abstract[27]|abstract[32]	giv[27]|giv[32]	_	_
4-33	692-694	as	abstract[27]|abstract[32]	giv[27]|giv[32]	_	_
4-34	695-710	next-generation	abstract[27]|abstract[32]|abstract|abstract[35]	giv[27]|giv[32]|new|new[35]	appos|appos	4-37[0_35]|4-37[0_35]
4-35	711-721	sequencing	abstract[27]|abstract[32]|abstract[35]	giv[27]|giv[32]|new[35]	_	_
4-36	722-723	(	abstract[27]	giv[27]	_	_
4-37	724-727	NGS	abstract[27]|abstract	giv[27]|giv	coref	11-23
4-38	728-729	)	abstract[27]	giv[27]	_	_
4-39	730-732	or	abstract[27]	giv[27]	_	_
4-40	733-742	multiplex	abstract[27]|place|abstract[39]	giv[27]|new|giv[39]	_	_
4-41	743-750	barcode	abstract[27]|abstract|abstract[39]	giv[27]|new|giv[39]	_	_
4-42	751-761	technology	abstract[27]|abstract[39]	giv[27]|giv[39]	_	_
4-43	762-763	(	_	_	_	_
4-44	764-766	e.	_	_	_	_
4-45	767-769	g.	_	_	_	_
4-46	770-771	,	_	_	_	_
4-47	772-782	NanoString	object	new	_	_
4-48	783-784	)	_	_	_	_
4-49	785-786	.	_	_	_	_

#Text=However , not all the available tools are validated for patients ’ selection in clinical practice , as shown in
5-1	787-794	However	_	_	_	_
5-2	795-796	,	_	_	_	_
5-3	797-800	not	_	_	_	_
5-4	801-804	all	object[41]	giv[41]	_	_
5-5	805-808	the	object[41]	giv[41]	_	_
5-6	809-818	available	object[41]	giv[41]	_	_
5-7	819-824	tools	object[41]	giv[41]	_	_
5-8	825-828	are	_	_	_	_
5-9	829-838	validated	_	_	_	_
5-10	839-842	for	_	_	_	_
5-11	843-851	patients	person[42]|event[43]	new[42]|new[43]	coref|coref|coref|coref	8-6[0_42]|23-6[147_43]|8-6[0_42]|23-6[147_43]
5-12	852-853	’	person[42]|event[43]	new[42]|new[43]	_	_
5-13	854-863	selection	event[43]	new[43]	_	_
5-14	864-866	in	event[43]	new[43]	_	_
5-15	867-875	clinical	event[43]|abstract[44]	new[43]|giv[44]	coref	25-7[165_44]
5-16	876-884	practice	event[43]|abstract[44]	new[43]|giv[44]	_	_
5-17	885-886	,	_	_	_	_
5-18	887-889	as	_	_	_	_
5-19	890-895	shown	_	_	_	_
5-20	896-898	in	_	_	_	_

#Text=Figure 1
6-1	899-905	Figure	object[45]	new[45]	_	_
6-2	906-907	1	object[45]	new[45]	_	_

#Text=.
7-1	908-909	.	_	_	_	_

#Text=Among new biomarkers to select patients for immunotherapy , the tumor mutational burden ( TMB ) has been shown a strong correlation with the response to some compounds .
8-1	910-915	Among	_	_	_	_
8-2	916-919	new	abstract[46]	new[46]	_	_
8-3	920-930	biomarkers	abstract[46]	new[46]	_	_
8-4	931-933	to	_	_	_	_
8-5	934-940	select	_	_	_	_
8-6	941-949	patients	person	giv	_	_
8-7	950-953	for	_	_	_	_
8-8	954-967	immunotherapy	abstract	giv	coref	23-11
8-9	968-969	,	_	_	_	_
8-10	970-973	the	abstract[50]	new[50]	appos	8-15[0_50]
8-11	974-979	tumor	abstract|abstract[50]	new|new[50]	coref	9-17
8-12	980-990	mutational	abstract[50]	new[50]	_	_
8-13	991-997	burden	abstract[50]	new[50]	_	_
8-14	998-999	(	_	_	_	_
8-15	1000-1003	TMB	abstract	giv	coref	9-1
8-16	1004-1005	)	_	_	_	_
8-17	1006-1009	has	_	_	_	_
8-18	1010-1014	been	_	_	_	_
8-19	1015-1020	shown	_	_	_	_
8-20	1021-1022	a	abstract[52]	new[52]	_	_
8-21	1023-1029	strong	abstract[52]	new[52]	_	_
8-22	1030-1041	correlation	abstract[52]	new[52]	_	_
8-23	1042-1046	with	abstract[52]	new[52]	_	_
8-24	1047-1050	the	abstract[52]|abstract[53]	new[52]|new[53]	coref	10-20[66_53]
8-25	1051-1059	response	abstract[52]|abstract[53]	new[52]|new[53]	_	_
8-26	1060-1062	to	abstract[52]|abstract[53]	new[52]|new[53]	_	_
8-27	1063-1067	some	abstract[52]|abstract[53]|substance[54]	new[52]|new[53]|new[54]	_	_
8-28	1068-1077	compounds	abstract[52]|abstract[53]|substance[54]	new[52]|new[53]|new[54]	_	_
8-29	1078-1079	.	_	_	_	_

#Text=TMB is defined by the total number of somatic nonsynonymous mutations per coding area of the tumor DNA .
9-1	1080-1083	TMB	abstract	giv	coref	10-8[64_0]
9-2	1084-1086	is	_	_	_	_
9-3	1087-1094	defined	_	_	_	_
9-4	1095-1097	by	_	_	_	_
9-5	1098-1101	the	quantity[56]	new[56]	_	_
9-6	1102-1107	total	quantity[56]	new[56]	_	_
9-7	1108-1114	number	quantity[56]	new[56]	_	_
9-8	1115-1117	of	quantity[56]	new[56]	_	_
9-9	1118-1125	somatic	quantity[56]|abstract[57]	new[56]|new[57]	_	_
9-10	1126-1139	nonsynonymous	quantity[56]|abstract[57]	new[56]|new[57]	_	_
9-11	1140-1149	mutations	quantity[56]|abstract[57]	new[56]|new[57]	_	_
9-12	1150-1153	per	quantity[56]|abstract[57]	new[56]|new[57]	_	_
9-13	1154-1160	coding	quantity[56]|abstract[57]|abstract|place[59]	new[56]|new[57]|new|new[59]	_	_
9-14	1161-1165	area	quantity[56]|abstract[57]|place[59]	new[56]|new[57]|new[59]	_	_
9-15	1166-1168	of	quantity[56]|abstract[57]|place[59]	new[56]|new[57]|new[59]	_	_
9-16	1169-1172	the	quantity[56]|abstract[57]|place[59]|abstract[61]	new[56]|new[57]|new[59]|new[61]	ana	10-1[0_61]
9-17	1173-1178	tumor	quantity[56]|abstract[57]|place[59]|abstract|abstract[61]	new[56]|new[57]|new[59]|giv|new[61]	coref	14-23
9-18	1179-1182	DNA	quantity[56]|abstract[57]|place[59]|abstract[61]	new[56]|new[57]|new[59]|new[61]	_	_
9-19	1183-1184	.	_	_	_	_

#Text=It has been hypothesized that tumors with a higher TMB are more likely to express neoantigens and to induce a more robust immune response in the presence of immune checkpoint inhibitors .
10-1	1185-1187	It	abstract	giv	_	_
10-2	1188-1191	has	_	_	_	_
10-3	1192-1196	been	_	_	_	_
10-4	1197-1209	hypothesized	_	_	_	_
10-5	1210-1214	that	_	_	_	_
10-6	1215-1221	tumors	object[63]	giv[63]	coref	18-4[121_63]
10-7	1222-1226	with	object[63]	giv[63]	_	_
10-8	1227-1228	a	object[63]|abstract[64]	giv[63]|giv[64]	coref	11-4[0_64]
10-9	1229-1235	higher	object[63]|abstract[64]	giv[63]|giv[64]	_	_
10-10	1236-1239	TMB	object[63]|abstract[64]	giv[63]|giv[64]	_	_
10-11	1240-1243	are	_	_	_	_
10-12	1244-1248	more	_	_	_	_
10-13	1249-1255	likely	_	_	_	_
10-14	1256-1258	to	_	_	_	_
10-15	1259-1266	express	_	_	_	_
10-16	1267-1278	neoantigens	abstract	new	_	_
10-17	1279-1282	and	_	_	_	_
10-18	1283-1285	to	_	_	_	_
10-19	1286-1292	induce	_	_	_	_
10-20	1293-1294	a	abstract[66]	giv[66]	coref	30-13[203_66]
10-21	1295-1299	more	abstract[66]	giv[66]	_	_
10-22	1300-1306	robust	abstract[66]	giv[66]	_	_
10-23	1307-1313	immune	abstract[66]	giv[66]	_	_
10-24	1314-1322	response	abstract[66]	giv[66]	_	_
10-25	1323-1325	in	_	_	_	_
10-26	1326-1329	the	abstract[67]	new[67]	_	_
10-27	1330-1338	presence	abstract[67]	new[67]	_	_
10-28	1339-1341	of	abstract[67]	new[67]	_	_
10-29	1342-1348	immune	abstract[67]|abstract|abstract[70]	new[67]|new|new[70]	_	_
10-30	1349-1359	checkpoint	abstract[67]|place|abstract[70]	new[67]|new|new[70]	_	_
10-31	1360-1370	inhibitors	abstract[67]|abstract[70]	new[67]|new[70]	_	_
10-32	1371-1372	.	_	_	_	_

#Text=Regrettably , the TMB analysis is considered expensive , time-consuming , and deceptive if the analyses are carried out with an unsuitable NGS panel .
11-1	1373-1384	Regrettably	_	_	_	_
11-2	1385-1386	,	_	_	_	_
11-3	1387-1390	the	abstract[72]	new[72]	coref	12-5[78_72]
11-4	1391-1394	TMB	abstract|abstract[72]	giv|new[72]	coref	12-5
11-5	1395-1403	analysis	abstract[72]	new[72]	_	_
11-6	1404-1406	is	_	_	_	_
11-7	1407-1417	considered	_	_	_	_
11-8	1418-1427	expensive	_	_	_	_
11-9	1428-1429	,	_	_	_	_
11-10	1430-1444	time-consuming	_	_	_	_
11-11	1445-1446	,	_	_	_	_
11-12	1447-1450	and	_	_	_	_
11-13	1451-1460	deceptive	_	_	_	_
11-14	1461-1463	if	_	_	_	_
11-15	1464-1467	the	abstract[73]	new[73]	coref	18-21[126_73]
11-16	1468-1476	analyses	abstract[73]	new[73]	_	_
11-17	1477-1480	are	_	_	_	_
11-18	1481-1488	carried	_	_	_	_
11-19	1489-1492	out	_	_	_	_
11-20	1493-1497	with	_	_	_	_
11-21	1498-1500	an	object[75]	new[75]	_	_
11-22	1501-1511	unsuitable	object[75]	new[75]	_	_
11-23	1512-1515	NGS	abstract|object[75]	giv|new[75]	coref	13-13[87_0]
11-24	1516-1521	panel	object[75]	new[75]	_	_
11-25	1522-1523	.	_	_	_	_

#Text=Another important facet in TMB analysis is represented by the lack of widely adopted guidelines and recommendations for its assessment and reporting .
12-1	1524-1531	Another	abstract[76]	new[76]	_	_
12-2	1532-1541	important	abstract[76]	new[76]	_	_
12-3	1542-1547	facet	abstract[76]	new[76]	_	_
12-4	1548-1550	in	abstract[76]	new[76]	_	_
12-5	1551-1554	TMB	abstract[76]|abstract|abstract[78]	new[76]|giv|giv[78]	coref|coref|coref|coref	13-3|16-3[104_78]|13-3|16-3[104_78]
12-6	1555-1563	analysis	abstract[76]|abstract[78]	new[76]|giv[78]	_	_
12-7	1564-1566	is	_	_	_	_
12-8	1567-1578	represented	_	_	_	_
12-9	1579-1581	by	_	_	_	_
12-10	1582-1585	the	abstract[79]	new[79]	_	_
12-11	1586-1590	lack	abstract[79]	new[79]	_	_
12-12	1591-1593	of	abstract[79]	new[79]	_	_
12-13	1594-1600	widely	abstract[79]|abstract[80]	new[79]|new[80]	coref	22-17[0_80]
12-14	1601-1608	adopted	abstract[79]|abstract[80]	new[79]|new[80]	_	_
12-15	1609-1619	guidelines	abstract[79]|abstract[80]	new[79]|new[80]	_	_
12-16	1620-1623	and	abstract[79]	new[79]	_	_
12-17	1624-1639	recommendations	abstract[79]|abstract[81]	new[79]|new[81]	_	_
12-18	1640-1643	for	abstract[79]|abstract[81]	new[79]|new[81]	_	_
12-19	1644-1647	its	abstract[79]|abstract[81]|abstract[82]	new[79]|new[81]|new[82]	_	_
12-20	1648-1658	assessment	abstract[79]|abstract[81]|abstract[82]	new[79]|new[81]|new[82]	_	_
12-21	1659-1662	and	abstract[79]|abstract[81]	new[79]|new[81]	_	_
12-22	1663-1672	reporting	abstract[79]|abstract[81]|abstract	new[79]|new[81]|new	_	_
12-23	1673-1674	.	_	_	_	_

#Text=Initially , TMB was determined using wide approaches ( e. g. , whole exome sequencing ) , but more focused gene panels are currently being explored .
13-1	1675-1684	Initially	_	_	_	_
13-2	1685-1686	,	_	_	_	_
13-3	1687-1690	TMB	abstract	giv	coref	14-9
13-4	1691-1694	was	_	_	_	_
13-5	1695-1705	determined	_	_	_	_
13-6	1706-1711	using	_	_	_	_
13-7	1712-1716	wide	abstract[85]	new[85]	_	_
13-8	1717-1727	approaches	abstract[85]	new[85]	_	_
13-9	1728-1729	(	_	_	_	_
13-10	1730-1732	e.	_	_	_	_
13-11	1733-1735	g.	_	_	_	_
13-12	1736-1737	,	_	_	_	_
13-13	1738-1743	whole	abstract[87]	giv[87]	_	_
13-14	1744-1749	exome	abstract|abstract[87]	new|giv[87]	_	_
13-15	1750-1760	sequencing	abstract[87]	giv[87]	_	_
13-16	1761-1762	)	_	_	_	_
13-17	1763-1764	,	_	_	_	_
13-18	1765-1768	but	_	_	_	_
13-19	1769-1773	more	_	_	_	_
13-20	1774-1781	focused	_	_	_	_
13-21	1782-1786	gene	abstract|person[89]	new|new[89]	coref|coref	15-7[102_89]|15-7[102_89]
13-22	1787-1793	panels	person[89]	new[89]	_	_
13-23	1794-1797	are	_	_	_	_
13-24	1798-1807	currently	_	_	_	_
13-25	1808-1813	being	_	_	_	_
13-26	1814-1822	explored	_	_	_	_
13-27	1823-1824	.	_	_	_	_

#Text=In addition , there are several indications that TMB is not a universal biomarker , as its value varies not only across tumor types but also across different genomic regions and during the time .
14-1	1825-1827	In	_	_	_	_
14-2	1828-1836	addition	_	_	_	_
14-3	1837-1838	,	_	_	_	_
14-4	1839-1844	there	_	_	_	_
14-5	1845-1848	are	_	_	_	_
14-6	1849-1856	several	abstract[90]	new[90]	_	_
14-7	1857-1868	indications	abstract[90]	new[90]	_	_
14-8	1869-1873	that	_	_	_	_
14-9	1874-1877	TMB	abstract	giv	coref	15-8
14-10	1878-1880	is	_	_	_	_
14-11	1881-1884	not	_	_	_	_
14-12	1885-1886	a	abstract[92]	new[92]	ana	14-17[0_92]
14-13	1887-1896	universal	abstract[92]	new[92]	_	_
14-14	1897-1906	biomarker	abstract[92]	new[92]	_	_
14-15	1907-1908	,	_	_	_	_
14-16	1909-1911	as	_	_	_	_
14-17	1912-1915	its	abstract|abstract[94]	giv|new[94]	coref|coref	29-7[196_94]|29-7[196_94]
14-18	1916-1921	value	abstract[94]	new[94]	_	_
14-19	1922-1928	varies	_	_	_	_
14-20	1929-1932	not	_	_	_	_
14-21	1933-1937	only	place[96]	new[96]	coref	20-15[140_96]
14-22	1938-1944	across	place[96]	new[96]	_	_
14-23	1945-1950	tumor	abstract|place[96]	giv|new[96]	coref	20-16
14-24	1951-1956	types	place[96]	new[96]	_	_
14-25	1957-1960	but	_	_	_	_
14-26	1961-1965	also	_	_	_	_
14-27	1966-1972	across	_	_	_	_
14-28	1973-1982	different	abstract[97]	new[97]	_	_
14-29	1983-1990	genomic	abstract[97]	new[97]	_	_
14-30	1991-1998	regions	abstract[97]	new[97]	_	_
14-31	1999-2002	and	_	_	_	_
14-32	2003-2009	during	_	_	_	_
14-33	2010-2013	the	time[98]	giv[98]	_	_
14-34	2014-2018	time	time[98]	giv[98]	_	_
14-35	2019-2020	.	_	_	_	_

#Text=This notion highlights the need for disease-specific TMB panels and thresholds .
15-1	2021-2025	This	abstract[99]	new[99]	_	_
15-2	2026-2032	notion	abstract[99]	new[99]	_	_
15-3	2033-2043	highlights	_	_	_	_
15-4	2044-2047	the	abstract[100]	new[100]	_	_
15-5	2048-2052	need	abstract[100]	new[100]	_	_
15-6	2053-2056	for	abstract[100]	new[100]	_	_
15-7	2057-2073	disease-specific	abstract[100]|person[102]	new[100]|giv[102]	_	_
15-8	2074-2077	TMB	abstract[100]|abstract|person[102]	new[100]|giv|giv[102]	_	_
15-9	2078-2084	panels	abstract[100]|person[102]	new[100]|giv[102]	_	_
15-10	2085-2088	and	abstract[100]|person[102]	new[100]|giv[102]	_	_
15-11	2089-2099	thresholds	abstract[100]|person[102]|abstract	new[100]|giv[102]|new	_	_
15-12	2100-2101	.	_	_	_	_

#Text=Likewise , the analysis of the MMR status is troubled by the vastity of the existing diagnostic methods in the substantial absence of companion diagnostic ( CD ) tests .
16-1	2102-2110	Likewise	_	_	_	_
16-2	2111-2112	,	_	_	_	_
16-3	2113-2116	the	abstract[104]	giv[104]	coref	23-15[150_104]
16-4	2117-2125	analysis	abstract[104]	giv[104]	_	_
16-5	2126-2128	of	abstract[104]	giv[104]	_	_
16-6	2129-2132	the	abstract[104]|abstract[106]	giv[104]|new[106]	_	_
16-7	2133-2136	MMR	abstract[104]|abstract|abstract[106]	giv[104]|new|new[106]	coref	17-4
16-8	2137-2143	status	abstract[104]|abstract[106]	giv[104]|new[106]	_	_
16-9	2144-2146	is	_	_	_	_
16-10	2147-2155	troubled	_	_	_	_
16-11	2156-2158	by	_	_	_	_
16-12	2159-2162	the	abstract[107]	new[107]	_	_
16-13	2163-2170	vastity	abstract[107]	new[107]	_	_
16-14	2171-2173	of	abstract[107]	new[107]	_	_
16-15	2174-2177	the	abstract[107]|abstract[108]	new[107]|new[108]	coref	22-14[143_108]
16-16	2178-2186	existing	abstract[107]|abstract[108]	new[107]|new[108]	_	_
16-17	2187-2197	diagnostic	abstract[107]|abstract[108]	new[107]|new[108]	_	_
16-18	2198-2205	methods	abstract[107]|abstract[108]	new[107]|new[108]	_	_
16-19	2206-2208	in	abstract[107]|abstract[108]	new[107]|new[108]	_	_
16-20	2209-2212	the	abstract[107]|abstract[108]|abstract[109]	new[107]|new[108]|new[109]	_	_
16-21	2213-2224	substantial	abstract[107]|abstract[108]|abstract[109]	new[107]|new[108]|new[109]	_	_
16-22	2225-2232	absence	abstract[107]|abstract[108]|abstract[109]	new[107]|new[108]|new[109]	_	_
16-23	2233-2235	of	abstract[107]|abstract[108]|abstract[109]	new[107]|new[108]|new[109]	_	_
16-24	2236-2245	companion	abstract[107]|abstract[108]|abstract[109]|abstract[110]	new[107]|new[108]|new[109]|new[110]	appos	16-27[0_110]
16-25	2246-2256	diagnostic	abstract[107]|abstract[108]|abstract[109]|abstract[110]	new[107]|new[108]|new[109]|new[110]	_	_
16-26	2257-2258	(	abstract[107]|abstract[108]|abstract[109]	new[107]|new[108]|new[109]	_	_
16-27	2259-2261	CD	abstract[107]|abstract[108]|abstract[109]|abstract	new[107]|new[108]|new[109]|giv	_	_
16-28	2262-2263	)	abstract[107]|abstract[108]|abstract[109]	new[107]|new[108]|new[109]	_	_
16-29	2264-2269	tests	abstract[107]|abstract[108]|abstract[109]|abstract	new[107]|new[108]|new[109]|new	_	_
16-30	2270-2271	.	_	_	_	_

#Text=In general , MMR IHC is mirrored by microsatellite instability ( MSI ) in endometrial and colorectal cancers .
17-1	2272-2274	In	_	_	_	_
17-2	2275-2282	general	person	new	_	_
17-3	2283-2284	,	_	_	_	_
17-4	2285-2288	MMR	abstract|abstract[115]	giv|giv[115]	_	_
17-5	2289-2292	IHC	abstract[115]	giv[115]	_	_
17-6	2293-2295	is	_	_	_	_
17-7	2296-2304	mirrored	_	_	_	_
17-8	2305-2307	by	_	_	_	_
17-9	2308-2322	microsatellite	abstract[116]	new[116]	appos	17-12[0_116]
17-10	2323-2334	instability	abstract[116]	new[116]	_	_
17-11	2335-2336	(	_	_	_	_
17-12	2337-2340	MSI	abstract	giv	coref	18-8
17-13	2341-2342	)	_	_	_	_
17-14	2343-2345	in	_	_	_	_
17-15	2346-2357	endometrial	place	new	_	_
17-16	2358-2361	and	_	_	_	_
17-17	2362-2372	colorectal	abstract[119]	new[119]	_	_
17-18	2373-2380	cancers	abstract[119]	new[119]	_	_
17-19	2381-2382	.	_	_	_	_

#Text=However , not all MMR-deficient tumors show MSI ( e. g. , breast cancers ) , questioning the interchangeability of these analyses as pan-cancer predictive tests .
18-1	2383-2390	However	_	_	_	_
18-2	2391-2392	,	_	_	_	_
18-3	2393-2396	not	_	_	_	_
18-4	2397-2400	all	object[121]	giv[121]	coref	19-25[134_121]
18-5	2401-2414	MMR-deficient	object|object[121]	new|giv[121]	_	_
18-6	2415-2421	tumors	object[121]	giv[121]	_	_
18-7	2422-2426	show	_	_	_	_
18-8	2427-2430	MSI	abstract	giv	appos	18-10[123_0]
18-9	2431-2432	(	_	_	_	_
18-10	2433-2435	e.	abstract[123]	giv[123]	_	_
18-11	2436-2438	g.	abstract[123]	giv[123]	_	_
18-12	2439-2440	,	_	_	_	_
18-13	2441-2447	breast	place	new	_	_
18-14	2448-2455	cancers	_	_	_	_
18-15	2456-2457	)	_	_	_	_
18-16	2458-2459	,	_	_	_	_
18-17	2460-2471	questioning	_	_	_	_
18-18	2472-2475	the	abstract[125]	new[125]	_	_
18-19	2476-2494	interchangeability	abstract[125]	new[125]	_	_
18-20	2495-2497	of	abstract[125]	new[125]	_	_
18-21	2498-2503	these	abstract[125]|abstract[126]	new[125]|giv[126]	_	_
18-22	2504-2512	analyses	abstract[125]|abstract[126]	new[125]|giv[126]	_	_
18-23	2513-2515	as	abstract[125]|abstract[126]	new[125]|giv[126]	_	_
18-24	2516-2526	pan-cancer	abstract[125]|abstract[126]	new[125]|giv[126]	_	_
18-25	2527-2537	predictive	abstract[125]|abstract[126]	new[125]|giv[126]	_	_
18-26	2538-2543	tests	abstract[125]|abstract[126]	new[125]|giv[126]	_	_
18-27	2544-2545	.	_	_	_	_

#Text=Hence , MMR/MSI assays have been originally developed by geneticists to identify Lynch syndrome families and not for choosing the optimal drug to treat acquired tumors .
19-1	2546-2551	Hence	_	_	_	_
19-2	2552-2553	,	_	_	_	_
19-3	2554-2561	MMR/MSI	organization|abstract[128]	new|giv[128]	coref|coref	22-11[0_128]|22-11[0_128]
19-4	2562-2568	assays	abstract[128]	giv[128]	_	_
19-5	2569-2573	have	_	_	_	_
19-6	2574-2578	been	_	_	_	_
19-7	2579-2589	originally	_	_	_	_
19-8	2590-2599	developed	_	_	_	_
19-9	2600-2602	by	_	_	_	_
19-10	2603-2614	geneticists	abstract	new	_	_
19-11	2615-2617	to	_	_	_	_
19-12	2618-2626	identify	_	_	_	_
19-13	2627-2632	Lynch	person|abstract[132]	new|new[132]	_	_
19-14	2633-2641	syndrome	event|abstract[132]	new|new[132]	_	_
19-15	2642-2650	families	abstract[132]	new[132]	_	_
19-16	2651-2654	and	_	_	_	_
19-17	2655-2658	not	_	_	_	_
19-18	2659-2662	for	_	_	_	_
19-19	2663-2671	choosing	_	_	_	_
19-20	2672-2675	the	substance[133]	giv[133]	_	_
19-21	2676-2683	optimal	substance[133]	giv[133]	_	_
19-22	2684-2688	drug	substance[133]	giv[133]	_	_
19-23	2689-2691	to	_	_	_	_
19-24	2692-2697	treat	_	_	_	_
19-25	2698-2706	acquired	object[134]	giv[134]	_	_
19-26	2707-2713	tumors	object[134]	giv[134]	_	_
19-27	2714-2715	.	_	_	_	_

#Text=Given the wide heterogeneity in the repertoire of molecular alterations in immune-related genes across different tumor types (
20-1	2716-2721	Given	_	_	_	_
20-2	2722-2725	the	abstract[135]	new[135]	_	_
20-3	2726-2730	wide	abstract[135]	new[135]	_	_
20-4	2731-2744	heterogeneity	abstract[135]	new[135]	_	_
20-5	2745-2747	in	abstract[135]	new[135]	_	_
20-6	2748-2751	the	abstract[135]|abstract[136]	new[135]|new[136]	coref	32-26[220_136]
20-7	2752-2762	repertoire	abstract[135]|abstract[136]	new[135]|new[136]	_	_
20-8	2763-2765	of	abstract[135]|abstract[136]	new[135]|new[136]	_	_
20-9	2766-2775	molecular	abstract[135]|abstract[136]|abstract[137]	new[135]|new[136]|new[137]	_	_
20-10	2776-2787	alterations	abstract[135]|abstract[136]|abstract[137]	new[135]|new[136]|new[137]	_	_
20-11	2788-2790	in	abstract[135]|abstract[136]|abstract[137]	new[135]|new[136]|new[137]	_	_
20-12	2791-2805	immune-related	abstract[135]|abstract[136]|abstract[137]|abstract[138]	new[135]|new[136]|new[137]|new[138]	_	_
20-13	2806-2811	genes	abstract[135]|abstract[136]|abstract[137]|abstract[138]	new[135]|new[136]|new[137]|new[138]	_	_
20-14	2812-2818	across	abstract[135]|abstract[136]|abstract[137]|abstract[138]	new[135]|new[136]|new[137]|new[138]	_	_
20-15	2819-2828	different	abstract[135]|abstract[136]|abstract[137]|abstract[138]|place[140]	new[135]|new[136]|new[137]|new[138]|giv[140]	coref	26-22[175_140]
20-16	2829-2834	tumor	abstract[135]|abstract[136]|abstract[137]|abstract[138]|abstract|place[140]	new[135]|new[136]|new[137]|new[138]|giv|giv[140]	coref	26-23
20-17	2835-2840	types	abstract[135]|abstract[136]|abstract[137]|abstract[138]|place[140]	new[135]|new[136]|new[137]|new[138]|giv[140]	_	_
20-18	2841-2842	(	_	_	_	_

#Text=Figure 2
21-1	2843-2849	Figure	abstract[141]	new[141]	_	_
21-2	2850-2851	2	abstract[141]	new[141]	_	_

#Text=) , novel , efficient , reproducible , and reliable techniques coupled with tumor-specific methods and guidelines are needed .
22-1	2852-2853	)	_	_	_	_
22-2	2854-2855	,	_	_	_	_
22-3	2856-2861	novel	_	_	_	_
22-4	2862-2863	,	_	_	_	_
22-5	2864-2873	efficient	_	_	_	_
22-6	2874-2875	,	_	_	_	_
22-7	2876-2888	reproducible	_	_	_	_
22-8	2889-2890	,	_	_	_	_
22-9	2891-2894	and	_	_	_	_
22-10	2895-2903	reliable	_	_	_	_
22-11	2904-2914	techniques	abstract	giv	_	_
22-12	2915-2922	coupled	_	_	_	_
22-13	2923-2927	with	_	_	_	_
22-14	2928-2942	tumor-specific	abstract[143]	giv[143]	_	_
22-15	2943-2950	methods	abstract[143]	giv[143]	_	_
22-16	2951-2954	and	abstract[143]	giv[143]	_	_
22-17	2955-2965	guidelines	abstract[143]|abstract	giv[143]|giv	coref	26-13[173_0]
22-18	2966-2969	are	_	_	_	_
22-19	2970-2976	needed	_	_	_	_
22-20	2977-2978	.	_	_	_	_

#Text=Another important issue related to the patient ’s selection for immunotherapy is represented by the PD-L1 analysis by IHC .
23-1	2979-2986	Another	abstract[145]	new[145]	_	_
23-2	2987-2996	important	abstract[145]	new[145]	_	_
23-3	2997-3002	issue	abstract[145]	new[145]	_	_
23-4	3003-3010	related	_	_	_	_
23-5	3011-3013	to	_	_	_	_
23-6	3014-3017	the	event[147]	giv[147]	_	_
23-7	3018-3025	patient	person[146]|event[147]	new[146]|giv[147]	_	_
23-8	3026-3028	’s	person[146]|event[147]	new[146]|giv[147]	_	_
23-9	3029-3038	selection	event[147]	giv[147]	_	_
23-10	3039-3042	for	event[147]	giv[147]	_	_
23-11	3043-3056	immunotherapy	event[147]|abstract	giv[147]|giv	_	_
23-12	3057-3059	is	_	_	_	_
23-13	3060-3071	represented	_	_	_	_
23-14	3072-3074	by	_	_	_	_
23-15	3075-3078	the	abstract[150]	giv[150]	_	_
23-16	3079-3084	PD-L1	abstract|abstract[150]	new|giv[150]	coref	24-20
23-17	3085-3093	analysis	abstract[150]	giv[150]	_	_
23-18	3094-3096	by	abstract[150]	giv[150]	_	_
23-19	3097-3100	IHC	abstract[150]|person	giv[150]|new	_	_
23-20	3101-3102	.	_	_	_	_

#Text=In this respect , important harmonization efforts have been made to standardize both the preanalytical and interpretative phases of PD-L1 testing , at least in non-small cell lung cancer ( NSCLC ) .
24-1	3103-3105	In	_	_	_	_
24-2	3106-3110	this	abstract[152]	new[152]	_	_
24-3	3111-3118	respect	abstract[152]	new[152]	_	_
24-4	3119-3120	,	_	_	_	_
24-5	3121-3130	important	abstract[154]	new[154]	_	_
24-6	3131-3144	harmonization	abstract|abstract[154]	new|new[154]	_	_
24-7	3145-3152	efforts	abstract[154]	new[154]	_	_
24-8	3153-3157	have	_	_	_	_
24-9	3158-3162	been	_	_	_	_
24-10	3163-3167	made	_	_	_	_
24-11	3168-3170	to	_	_	_	_
24-12	3171-3182	standardize	_	_	_	_
24-13	3183-3187	both	abstract[155]	new[155]	_	_
24-14	3188-3191	the	abstract[155]	new[155]	_	_
24-15	3192-3205	preanalytical	abstract[155]	new[155]	_	_
24-16	3206-3209	and	abstract[155]	new[155]	_	_
24-17	3210-3224	interpretative	abstract[155]	new[155]	_	_
24-18	3225-3231	phases	abstract[155]	new[155]	_	_
24-19	3232-3234	of	abstract[155]	new[155]	_	_
24-20	3235-3240	PD-L1	abstract[155]|abstract|abstract[157]	new[155]|giv|new[157]	coref|coref|coref|coref	25-4|25-4[164_157]|25-4|25-4[164_157]
24-21	3241-3248	testing	abstract[155]|abstract[157]	new[155]|new[157]	_	_
24-22	3249-3250	,	_	_	_	_
24-23	3251-3253	at	abstract[160]	new[160]	coref	27-14[180_160]
24-24	3254-3259	least	abstract[160]	new[160]	_	_
24-25	3260-3262	in	abstract[160]	new[160]	_	_
24-26	3263-3272	non-small	abstract[160]	new[160]	_	_
24-27	3273-3277	cell	place|abstract[160]	new|new[160]	coref	31-12
24-28	3278-3282	lung	object|abstract[160]	new|new[160]	_	_
24-29	3283-3289	cancer	abstract[160]	new[160]	_	_
24-30	3290-3291	(	_	_	_	_
24-31	3292-3297	NSCLC	organization	new	_	_
24-32	3298-3299	)	_	_	_	_
24-33	3300-3301	.	_	_	_	_

#Text=The reproducibility of PD-L1 testing in real-life clinical practice evaluated both for “ closed ” and “ open ” platforms , showed overlapping results , particularly when the 22C3 antibody clone was used .
25-1	3302-3305	The	abstract[162]	new[162]	_	_
25-2	3306-3321	reproducibility	abstract[162]	new[162]	_	_
25-3	3322-3324	of	abstract[162]	new[162]	_	_
25-4	3325-3330	PD-L1	abstract[162]|object|abstract[164]	new[162]|giv|giv[164]	_	_
25-5	3331-3338	testing	abstract[162]|abstract[164]	new[162]|giv[164]	_	_
25-6	3339-3341	in	abstract[162]|abstract[164]	new[162]|giv[164]	_	_
25-7	3342-3351	real-life	abstract[162]|abstract[164]|abstract[165]	new[162]|giv[164]|giv[165]	ana	25-11[166_165]
25-8	3352-3360	clinical	abstract[162]|abstract[164]|abstract[165]	new[162]|giv[164]|giv[165]	_	_
25-9	3361-3369	practice	abstract[162]|abstract[164]|abstract[165]	new[162]|giv[164]|giv[165]	_	_
25-10	3370-3379	evaluated	_	_	_	_
25-11	3380-3384	both	abstract[166]	giv[166]	_	_
25-12	3385-3388	for	abstract[166]	giv[166]	_	_
25-13	3389-3390	“	abstract[166]	giv[166]	_	_
25-14	3391-3397	closed	abstract[166]	giv[166]	_	_
25-15	3398-3399	”	abstract[166]	giv[166]	_	_
25-16	3400-3403	and	abstract[166]	giv[166]	_	_
25-17	3404-3405	“	abstract[166]|abstract[167]	giv[166]|new[167]	_	_
25-18	3406-3410	open	abstract[166]|abstract[167]	giv[166]|new[167]	_	_
25-19	3411-3412	”	abstract[166]|abstract[167]	giv[166]|new[167]	_	_
25-20	3413-3422	platforms	abstract[166]|abstract[167]	giv[166]|new[167]	_	_
25-21	3423-3424	,	_	_	_	_
25-22	3425-3431	showed	_	_	_	_
25-23	3432-3443	overlapping	abstract[168]	new[168]	_	_
25-24	3444-3451	results	abstract[168]	new[168]	_	_
25-25	3452-3453	,	_	_	_	_
25-26	3454-3466	particularly	_	_	_	_
25-27	3467-3471	when	_	_	_	_
25-28	3472-3475	the	object[170]	new[170]	_	_
25-29	3476-3480	22C3	object[170]	new[170]	_	_
25-30	3481-3489	antibody	substance|object[170]	new|new[170]	_	_
25-31	3490-3495	clone	object[170]	new[170]	_	_
25-32	3496-3499	was	_	_	_	_
25-33	3500-3504	used	_	_	_	_
25-34	3505-3506	.	_	_	_	_

#Text=On the other hand , there are several clues to advise that the same interpretation guidelines should not be translated across different tumor types .
26-1	3507-3509	On	_	_	_	_
26-2	3510-3513	the	_	_	_	_
26-3	3514-3519	other	_	_	_	_
26-4	3520-3524	hand	_	_	_	_
26-5	3525-3526	,	_	_	_	_
26-6	3527-3532	there	_	_	_	_
26-7	3533-3536	are	_	_	_	_
26-8	3537-3544	several	abstract[171]	new[171]	_	_
26-9	3545-3550	clues	abstract[171]	new[171]	_	_
26-10	3551-3553	to	_	_	_	_
26-11	3554-3560	advise	_	_	_	_
26-12	3561-3565	that	_	_	_	_
26-13	3566-3569	the	abstract[173]	giv[173]	_	_
26-14	3570-3574	same	abstract[173]	giv[173]	_	_
26-15	3575-3589	interpretation	abstract|abstract[173]	new|giv[173]	_	_
26-16	3590-3600	guidelines	abstract[173]	giv[173]	_	_
26-17	3601-3607	should	_	_	_	_
26-18	3608-3611	not	_	_	_	_
26-19	3612-3614	be	_	_	_	_
26-20	3615-3625	translated	_	_	_	_
26-21	3626-3632	across	_	_	_	_
26-22	3633-3642	different	place[175]	giv[175]	_	_
26-23	3643-3648	tumor	abstract|place[175]	giv|giv[175]	coref	27-5
26-24	3649-3654	types	place[175]	giv[175]	_	_
26-25	3655-3656	.	_	_	_	_

#Text=For example , the tumor proportion score ( TPS ) works perfectly for lung cancer but not for head and neck cancer , where the combined positive score ( CPS ) is more reliable .
27-1	3657-3660	For	_	_	_	_
27-2	3661-3668	example	_	_	_	_
27-3	3669-3670	,	_	_	_	_
27-4	3671-3674	the	abstract[178]	new[178]	appos	27-9[0_178]
27-5	3675-3680	tumor	abstract|abstract[178]	giv|new[178]	coref	28-33
27-6	3681-3691	proportion	abstract|abstract[178]	new|new[178]	_	_
27-7	3692-3697	score	abstract[178]	new[178]	_	_
27-8	3698-3699	(	_	_	_	_
27-9	3700-3703	TPS	abstract	giv	coref	27-25[184_0]
27-10	3704-3705	)	_	_	_	_
27-11	3706-3711	works	_	_	_	_
27-12	3712-3721	perfectly	_	_	_	_
27-13	3722-3725	for	_	_	_	_
27-14	3726-3730	lung	abstract[180]	giv[180]	coref	27-21[183_180]
27-15	3731-3737	cancer	abstract[180]	giv[180]	_	_
27-16	3738-3741	but	_	_	_	_
27-17	3742-3745	not	_	_	_	_
27-18	3746-3749	for	_	_	_	_
27-19	3750-3754	head	object	new	_	_
27-20	3755-3758	and	_	_	_	_
27-21	3759-3763	neck	object|abstract[183]	new|giv[183]	_	_
27-22	3764-3770	cancer	abstract[183]	giv[183]	_	_
27-23	3771-3772	,	_	_	_	_
27-24	3773-3778	where	_	_	_	_
27-25	3779-3782	the	abstract[184]	giv[184]	coref	29-12[198_184]
27-26	3783-3791	combined	abstract[184]	giv[184]	_	_
27-27	3792-3800	positive	abstract[184]	giv[184]	_	_
27-28	3801-3806	score	abstract[184]	giv[184]	_	_
27-29	3807-3808	(	_	_	_	_
27-30	3809-3812	CPS	object	new	coref	29-2[195_0]
27-31	3813-3814	)	_	_	_	_
27-32	3815-3817	is	_	_	_	_
27-33	3818-3822	more	_	_	_	_
27-34	3823-3831	reliable	_	_	_	_
27-35	3832-3833	.	_	_	_	_

#Text=These two scoring systems are rather different , given that the former considers only the percentage of PD-L1-positive neoplastic cells , while the latter combines all PD-L1-positive cells ( i. e. , tumor cells , lymphocytes , and macrophages ) into the following formula .
28-1	3834-3839	These	abstract[186]	new[186]	_	_
28-2	3840-3843	two	abstract[186]	new[186]	_	_
28-3	3844-3851	scoring	abstract[186]	new[186]	_	_
28-4	3852-3859	systems	abstract[186]	new[186]	_	_
28-5	3860-3863	are	_	_	_	_
28-6	3864-3870	rather	_	_	_	_
28-7	3871-3880	different	_	_	_	_
28-8	3881-3882	,	_	_	_	_
28-9	3883-3888	given	_	_	_	_
28-10	3889-3893	that	_	_	_	_
28-11	3894-3897	the	_	_	_	_
28-12	3898-3904	former	_	_	_	_
28-13	3905-3914	considers	_	_	_	_
28-14	3915-3919	only	quantity[187]	new[187]	_	_
28-15	3920-3923	the	quantity[187]	new[187]	_	_
28-16	3924-3934	percentage	quantity[187]	new[187]	_	_
28-17	3935-3937	of	quantity[187]	new[187]	_	_
28-18	3938-3952	PD-L1-positive	quantity[187]|object[188]	new[187]|new[188]	coref	28-26[189_188]
28-19	3953-3963	neoplastic	quantity[187]|object[188]	new[187]|new[188]	_	_
28-20	3964-3969	cells	quantity[187]|object[188]	new[187]|new[188]	_	_
28-21	3970-3971	,	_	_	_	_
28-22	3972-3977	while	_	_	_	_
28-23	3978-3981	the	_	_	_	_
28-24	3982-3988	latter	_	_	_	_
28-25	3989-3997	combines	_	_	_	_
28-26	3998-4001	all	object[189]	giv[189]	coref	28-33[191_189]
28-27	4002-4016	PD-L1-positive	object[189]	giv[189]	_	_
28-28	4017-4022	cells	object[189]	giv[189]	_	_
28-29	4023-4024	(	_	_	_	_
28-30	4025-4027	i.	_	_	_	_
28-31	4028-4030	e.	_	_	_	_
28-32	4031-4032	,	_	_	_	_
28-33	4033-4038	tumor	abstract|object[191]	giv|giv[191]	appos|coref|appos|coref	28-36[0_191]|31-21|28-36[0_191]|31-21
28-34	4039-4044	cells	object[191]	giv[191]	_	_
28-35	4045-4046	,	_	_	_	_
28-36	4047-4058	lymphocytes	abstract	giv	appos	28-39[193_0]
28-37	4059-4060	,	_	_	_	_
28-38	4061-4064	and	_	_	_	_
28-39	4065-4076	macrophages	object[193]	giv[193]	coref	32-13[217_193]
28-40	4077-4078	)	object[193]	giv[193]	_	_
28-41	4079-4083	into	object[193]	giv[193]	_	_
28-42	4084-4087	the	object[193]|abstract[194]	giv[193]|new[194]	_	_
28-43	4088-4097	following	object[193]|abstract[194]	giv[193]|new[194]	_	_
28-44	4098-4105	formula	object[193]|abstract[194]	giv[193]|new[194]	_	_
28-45	4106-4107	.	_	_	_	_

#Text=Although the CPS can theoretically exceed the value of 100 , the maximum score is defined as 100 .
29-1	4108-4116	Although	_	_	_	_
29-2	4117-4120	the	object[195]	giv[195]	_	_
29-3	4121-4124	CPS	object[195]	giv[195]	_	_
29-4	4125-4128	can	_	_	_	_
29-5	4129-4142	theoretically	_	_	_	_
29-6	4143-4149	exceed	_	_	_	_
29-7	4150-4153	the	abstract[196]	giv[196]	_	_
29-8	4154-4159	value	abstract[196]	giv[196]	_	_
29-9	4160-4162	of	abstract[196]	giv[196]	_	_
29-10	4163-4166	100	abstract[196]|quantity	giv[196]|new	coref	29-18
29-11	4167-4168	,	_	_	_	_
29-12	4169-4172	the	abstract[198]	giv[198]	_	_
29-13	4173-4180	maximum	abstract[198]	giv[198]	_	_
29-14	4181-4186	score	abstract[198]	giv[198]	_	_
29-15	4187-4189	is	_	_	_	_
29-16	4190-4197	defined	_	_	_	_
29-17	4198-4200	as	_	_	_	_
29-18	4201-4204	100	quantity	giv	_	_
29-19	4205-4206	.	_	_	_	_

#Text=Fascinating perspectives are being provided by experimental models addressing the plasticity of the cellular inflammatory response of the host .
30-1	4207-4218	Fascinating	abstract[200]	new[200]	_	_
30-2	4219-4231	perspectives	abstract[200]	new[200]	_	_
30-3	4232-4235	are	_	_	_	_
30-4	4236-4241	being	_	_	_	_
30-5	4242-4250	provided	_	_	_	_
30-6	4251-4253	by	_	_	_	_
30-7	4254-4266	experimental	abstract[201]	new[201]	_	_
30-8	4267-4273	models	abstract[201]	new[201]	_	_
30-9	4274-4284	addressing	_	_	_	_
30-10	4285-4288	the	abstract[202]	new[202]	_	_
30-11	4289-4299	plasticity	abstract[202]	new[202]	_	_
30-12	4300-4302	of	abstract[202]	new[202]	_	_
30-13	4303-4306	the	abstract[202]|abstract[203]	new[202]|giv[203]	_	_
30-14	4307-4315	cellular	abstract[202]|abstract[203]	new[202]|giv[203]	_	_
30-15	4316-4328	inflammatory	abstract[202]|abstract[203]	new[202]|giv[203]	_	_
30-16	4329-4337	response	abstract[202]|abstract[203]	new[202]|giv[203]	_	_
30-17	4338-4340	of	abstract[202]|abstract[203]	new[202]|giv[203]	_	_
30-18	4341-4344	the	abstract[202]|abstract[203]|person[204]	new[202]|giv[203]|new[204]	_	_
30-19	4345-4349	host	abstract[202]|abstract[203]|person[204]	new[202]|giv[203]|new[204]	_	_
30-20	4350-4351	.	_	_	_	_

#Text=There are several lines of evidence to suggest that the myeloid-derived cell function is a finely tuned mechanism to control tumor growth .
31-1	4352-4357	There	_	_	_	_
31-2	4358-4361	are	_	_	_	_
31-3	4362-4369	several	abstract[205]	new[205]	_	_
31-4	4370-4375	lines	abstract[205]	new[205]	_	_
31-5	4376-4378	of	abstract[205]	new[205]	_	_
31-6	4379-4387	evidence	abstract[205]|abstract	new[205]|new	_	_
31-7	4388-4390	to	_	_	_	_
31-8	4391-4398	suggest	_	_	_	_
31-9	4399-4403	that	_	_	_	_
31-10	4404-4407	the	abstract[208]	new[208]	coref	31-15[209_208]
31-11	4408-4423	myeloid-derived	abstract[208]	new[208]	_	_
31-12	4424-4428	cell	object|abstract[208]	giv|new[208]	_	_
31-13	4429-4437	function	abstract[208]	new[208]	_	_
31-14	4438-4440	is	_	_	_	_
31-15	4441-4442	a	abstract[209]	giv[209]	ana	32-10[0_209]
31-16	4443-4449	finely	abstract[209]	giv[209]	_	_
31-17	4450-4455	tuned	abstract[209]	giv[209]	_	_
31-18	4456-4465	mechanism	abstract[209]	giv[209]	_	_
31-19	4466-4468	to	_	_	_	_
31-20	4469-4476	control	_	_	_	_
31-21	4477-4482	tumor	abstract|abstract[211]	giv|new[211]	ana|coref|ana|coref	32-3[212_211]|32-14|32-3[212_211]|32-14
31-22	4483-4489	growth	abstract[211]	new[211]	_	_
31-23	4490-4491	.	_	_	_	_

#Text=Specifically , both in local and hematopoietic niches , its crosstalk with the tumor cells as well as with exogenous stimuli , is based on the microbiota repertoire .
32-1	4492-4504	Specifically	_	_	_	_
32-2	4505-4506	,	_	_	_	_
32-3	4507-4511	both	abstract[212]	giv[212]	_	_
32-4	4512-4514	in	abstract[212]	giv[212]	_	_
32-5	4515-4520	local	abstract[212]|place[213]	giv[212]|new[213]	_	_
32-6	4521-4524	and	abstract[212]|place[213]	giv[212]|new[213]	_	_
32-7	4525-4538	hematopoietic	abstract[212]|place[213]	giv[212]|new[213]	_	_
32-8	4539-4545	niches	abstract[212]|place[213]	giv[212]|new[213]	_	_
32-9	4546-4547	,	_	_	_	_
32-10	4548-4551	its	abstract|abstract[215]	giv|new[215]	_	_
32-11	4552-4561	crosstalk	abstract[215]	new[215]	_	_
32-12	4562-4566	with	abstract[215]	new[215]	_	_
32-13	4567-4570	the	abstract[215]|object[217]	new[215]|giv[217]	_	_
32-14	4571-4576	tumor	abstract[215]|abstract|object[217]	new[215]|giv|giv[217]	_	_
32-15	4577-4582	cells	abstract[215]|object[217]	new[215]|giv[217]	_	_
32-16	4583-4585	as	_	_	_	_
32-17	4586-4590	well	_	_	_	_
32-18	4591-4593	as	_	_	_	_
32-19	4594-4598	with	_	_	_	_
32-20	4599-4608	exogenous	abstract[218]	new[218]	_	_
32-21	4609-4616	stimuli	abstract[218]	new[218]	_	_
32-22	4617-4618	,	_	_	_	_
32-23	4619-4621	is	_	_	_	_
32-24	4622-4627	based	_	_	_	_
32-25	4628-4630	on	_	_	_	_
32-26	4631-4634	the	abstract[220]	giv[220]	_	_
32-27	4635-4645	microbiota	person|abstract[220]	new|giv[220]	_	_
32-28	4646-4656	repertoire	abstract[220]	giv[220]	_	_
32-29	4657-4658	.	_	_	_	_
